- Home
- NRIM vs PRTC Comparison
NRIM vs PRTC Comparison
Compare NRIM & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIM
- PRTC
- Stock Information
- Founded
- NRIM 1990
- PRTC 2015
- Country
- NRIM United States
- PRTC United States
- Employees
- NRIM N/A
- PRTC N/A
- Industry
- NRIM Savings Institutions
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- NRIM Finance
- PRTC Health Care
- Exchange
- NRIM Nasdaq
- PRTC Nasdaq
- Market Cap
- NRIM 444.5M
- PRTC 428.7M
- IPO Year
- NRIM N/A
- PRTC N/A
- Fundamental
- Price
- NRIM $22.14
- PRTC $17.75
- Analyst Decision
- NRIM
- PRTC
- Analyst Count
- NRIM 0
- PRTC 0
- Target Price
- NRIM N/A
- PRTC N/A
- AVG Volume (30 Days)
- NRIM 104.5K
- PRTC 1.6K
- Earning Date
- NRIM 10-22-2025
- PRTC 08-28-2025
- Dividend Yield
- NRIM 2.89%
- PRTC N/A
- EPS Growth
- NRIM 91.08
- PRTC N/A
- EPS
- NRIM 2.80
- PRTC 0.20
- Revenue
- NRIM $201,544,000.00
- PRTC $6,391,000.00
- Revenue This Year
- NRIM $11.35
- PRTC N/A
- Revenue Next Year
- NRIM $7.32
- PRTC N/A
- P/E Ratio
- NRIM $7.89
- PRTC $8.14
- Revenue Growth
- NRIM 42.34
- PRTC 1265.60
- 52 Week Low
- NRIM $15.92
- PRTC $13.30
- 52 Week High
- NRIM $25.05
- PRTC $24.99
- Technical
- Relative Strength Index (RSI)
- NRIM 26.01
- PRTC 50.95
- Support Level
- NRIM $21.68
- PRTC $17.00
- Resistance Level
- NRIM $23.12
- PRTC $17.85
- Average True Range (ATR)
- NRIM 0.69
- PRTC 0.18
- MACD
- NRIM 2.22
- PRTC -0.07
- Stochastic Oscillator
- NRIM 72.26
- PRTC 48.00
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.